Current applications and perspectives of diagnostic nuclear medicine in oncology

International Journal of Oncology

Volumn 14, Issue 5, 1999, Pages 877-890

  Bombardieri, E ^a   Carrio, I ^b   Gonzalez, P ^c   Serafini, A ^d   Turner, J H ^e   Virgolini, I ^f   Maffioli, L ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITY OF CHILE   (Chile)

^d UNIVERSITY OF MIAMI HOSPITAL   (United States)

^e FREMANTLE HOSPITAL   (Australia)

^f UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Diagnostic oncology; Nuclear medicine developments; Nuclear medicine procedures

Indexed keywords

ARTICLE; FORECASTING; HUMAN; METHODOLOGY; NEOPLASM; NUCLEAR MEDICINE; ONCOLOGY;

FORECASTING; HUMANS; NEOPLASMS; NUCLEAR MEDICINE; RADIATION ONCOLOGY;

EID: 0033124881     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Wagner HN: Nuclear medicine: what it is what it does. In: Principles of Nuclear Medicine. Wagner HN, Szabo Z and Buchanan JW (eds). W.B. Saunders Co., Philadelphia, pp1-8, 1995.
2. Pauwels EKJ, McCready VR, Stoot JHMB and van Deurzen DFP: The mechanism of accumulation of tumour-localising radiopharmaceuticals. Eur J Nucl Med 25: 277-305, 1998.
3. Britton KE: Highlights lecture of the European Association of Nuclear Medicine and the World Federation of Nuclear Medicine and Biology Congress, Berlin 1998. Eur J Nucl Med 25: 1671-1684, 1998.
4. Datz FL: Abdominal abscess detection: gallium, In-111 and Tc99m labeled leukocytes, and polyclonal monoclonal antibodies. Semin Nucl Med 25: 51-64, 1996.
5. Bombardieri E, Crippa F, Maffioli L and Greco M: Nuclear medicine techniques for the study of breast cancer. Eur J Nucl Med (In press).
6. McLean R and Endo K: The nodule in the neck: the role of thyroid scanning. In: Nuclear Medicine. Murray IPC and Ell PJ (eds). Churchill Livingstone, pp667-676, 1994.
7. Pollycove M and Tono M: Blood volume. In: Diagnostic Nuclear Medicine. Gottschalk A, Hoffer PB and Potchen EJ (eds). Williams and Wilkins, Baltimore, pp690-698, 1988.
8. Seregni E, Chiti A and Bombardieri E: Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med 25: 639-658, 1998.
9. Freitas JE: Adrenal cortical and medullary imaging. Semin Nucl Med 25: 235-250, 1995.
10. Kubota K, Yamada S, Ito M and Yamada K: PET in diagnosing lung cancer. In: Clinical PET. Bares R and Lucignani G (eds). Kluwer Academic Publishers, pp55-66, 1996.
11. Brock CS, Meikle SR and Price P: Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology. Eur J Nucl Med 24: 691-705, 1997.
12. Zimny M, Bares R, Fas J, Adam G, Crenerius U, Dohmen B, Klever P, Sabri O, Schumpelick V and Buell U: FDG PET in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24: 678-682, 1997.
13. Gupta NC, Maloof J and Gunel EE: Probability of malignancy in solitary pulmonary nodules using fluorine-18 FDG PET. J Nucl Med 37: 943-948, 1996.
14. 18FDG uptake in soft tissue masses. Eur J Nucl Med 26: 22-30, 1999.
15. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, Luxen A and Reznik M: Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39: 778-785, 1998.
16. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25: 1255-1260, 1998.
17. McAfee R, Reba RC and Majd M: The musculo-skeletal system. In: Principles of Nuclear Medicine. Wagner HN, Szabo Z and Buchanan JW (eds). W.B. Saunders Co., Philadelphia, pp986-1028, 1995.
18. Lubin E, Mechlis-Frish S and Zatz S: Serum thyroglobulin an Iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 35: 257-262, 1994.
19. Hoefnagel CA: mIBG and somatostatin in oncology: role in the management of neural crest tumors. Eur J Nucl Med 21: 561-581, 1994.
20. Gasparini M, Bombardieri E, Castellani M, Tondini C, Maffioli L, Devizzi L and Gerundini P: Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma. J Nucl Med 39: 1586-1590, 1998.
21. Britton KE and Granowska M: The diagnostic role of radiolabelled antibodies. In: Nuclear Medicine. Murray IPC and Ell PJ (eds). Churchill Livingstone, pp779-800, 1994.
22. Zhu H, Jain RK and Baxter LT: Tumor pretargeting for radioimmunodetection and radioimmunotherapy. J Nucl Med 39: 65-76, 1998.
23. Bailey DL and Parker JA: Single photon emission computerized tomography. In: Nuclear Medicine. Murray IPC and Ell PJ (eds). Churchill Livingstone, pp1315-1326, 1994.
24. Price P: Is there a future for PET in oncology? Eur J Nucl Med 24: 587-589, 1997.
25. Keshtgar MRS and Ell PJ: Sentinel node detection and imaging. Eur J Nucl Med 26: 57-67, 1999.
26. Tiourina T, Arends B, Huysmans D, Rutten H, Lemaire B and Muller S: Evaluation of surgical gamma probes for radioguided sentinel node localisation. Eur J Nucl Med 25: 1224-1231, 1998.
27. Hoefnagel CA: Role of nuclear medicine in melanoma. Eur J Nucl Med 25: 1567-1574, 1998.
28. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, Costa A and De Cicco C: Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349: 1864-1867, 1997.
29. Beierwaltes WH: The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 8: 79-84, 1978.
30. Abdel-Dayem H, Larson SM and Macapinlac AS: Thallium-201 chloride: a tumor imaging agent. In: Nuclear Medicine. Murray IPC and Ell PJ (eds). Churchill Livingstone, pp727-735, 1994.
31. Sumiya H, Taki J, Nonomura A, Miyauchi T and Tonami T: Midcourse Thallium-201 scintigraphy to predict tumor response in bone and soft tissue tumors. J Nucl Med 39: 1600-1604, 1998.
32. Draisma AL, Maffioli L, Gasparini M, Savelli G, Pauwels E and Bombardieri E: Gallium-67 as a tumor-seeking agent in lymphomas. A review. Tumori 84: 434-441, 1998.
33. Maffioli L, Steens J, Pauwels E and Bombardieri E: Applications of 99mTc Sestamibi in oncology. Tumori 82: 12-21, 1996.
34. Piwnica-Worms D, Chiu ML and Budding M: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53: 977-984, 1993.
35. Del Vecchio S, Ciarmiello A, Potena M, Carriero MV, Mainolfi C, Botti G, Thomas R, Cerra M, D'Aiuto G, Tsuruo T and Salvatore M: In vivo detection of MDR-1 phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 24: 150-159, 1997.
36. Andrews DW, Das R, Kim S, Zhang J and Curtis M: Technetium-MIBI as a glioma imaging agent for the assessment of multidrug resistance. Neurosurgery 40: 1323-1332, 1997.
37. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergun EL and Bekdik CF: Association of tumor was-out rates and accumulation of Technetium-99m MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 39: 228-234, 1998.
38. Kostakoglu L, Guc D, Canpinar H, Kars A, Alper E, Kiratli P, Hayran M, Gunduz U and Kansu E: P-glycoprotein expression by Tc-99m-MIBI scintigraphy in hematologic malignancy. J Nucl Med 39: 1191-1197, 1998.
39. Lamberts SW, Reubi JC and Krenning EP: Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors. Acta Oncol 32: 167-170, 1993.
40. Bombardieri E, Crippa F, Cataldo I, Chiti A, Seregni E, Soresi E, Boffi R, Invernizzi G and Buraggi GL: Somatostatin receptor imaging of small cell lung cancer by means of In 111-DTPA Octreotide scintigraphy. Eur J Cancer 3: 184-188, 1995.
41. Sheidauer K, Muller S, Smolarz K, Brautigam P and Briele B: Tumor scintigraphy using 123I labelled estradiol in breast cancer receptor scintigraphy. Nuklearmedizin 30: 84-99, 1991.
42. Johnson SD and Welch MJ: PET imaging of breast cancer with Fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 42: 8-17, 1998.
43. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit and Foidart-Willems J: Oncological applications of positron emission tomography with F18-fluorodeoxyglucose. Eur J Nucl Med 23: 1642-1674, 1996.
44. Nakata B, Chung YS, Nishimura T, Sakurai Y, Okamura T, Kawabe J, Ochi H and Sowa M: 18F-FDG PET and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79: 695-699, 1997.
45. Yasuda S, Ide M, Takagi S and Shotsu A: F-18 FDG uptake in colonic carcinoma. Clin Nucl Med 23: 99-100, 1998.
46. Nutinen J, Leskinen S, Lindholm P, Soderstrom KO, Nagren K, Huhtala S and Minn H: Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas. Eur J Nucl Med 25: 729-735, 1998.
47. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Mohler M, Oberdorfer F and van Kaick G: F-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 39: 1197-1202, 1998.
48. Devizzi L, Maffioli L, Bonfante V, Viviani S, Balzarini L, Gasparini M, Valagussa P, Bombardieri E, Santoro A and Bonadonna G: Comparison of gallium scan, computed tomography and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 1: 53-56, 1997.
49. Ishibashi M, Nonoshita M, Uchida M, Kojima K, Tomita N, Matsumoto S, Tanaka K and Haybuchi N: Bone marrow uptake of thallium-201 before and after therapy in multiple myeloma. J Nucl Med 39: 473-475, 1998.
50. Hori A, Sumiya H, Taki J, Tonami N, Tsuchiya H and Tomita K: Thallium-201 SPECT in differentiating bone infarction from metastatic lesions in osteosarcoma. Clin Nucl Med 22: 717-718, 1997.
51. Carril JM, Quirce R, Serrano J, Banzo I, Jimenez-Bonilla JF, Tabuenca O and Barquin RG: Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer. J Nucl Med 38: 686-692, 1997.
52. Maffioli L, Gasparini M, Chiti A, Gramaglia A, Mongioj V, Pozzi AL and Bombardieri E: Clinical role of Tc99m Sestamibi SPECT in evaluating pretreated patients with brain tumors. Eur J Nucl Med 23: 308-311, 1996.
53. 131I in patients with metastatic thyroid carcinoma. Nucl Med Commun 18: 3-9, 1997.
54. Resinger I, Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A, Kettner B, Otto HJ, Schmidt S and Munz DL: Somatostatin receptor scintigraphy in small cell lung cancer: results of a multicenter study. J Nucl Med 39: 224-227, 1998.
55. Soler C, Perrot JL, Thieffet O, Beauchesne P, Lanthier K, Boucheron S, Dubois F and Cambazard F: The role of technetium-99m sestamibi SPET in the follow-up of malignant melanoma and the detection of lymph node metastases. Eur J Nucl Med 24: 1522-1525, 1997.
56. 111In-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 159: 2041-2046, 1998.
57. Wahl RL, Zasadny K and Helvie M: Metabolic monitoring of breast cancer chemohormonotherapy using PET. J Clin Oncol 11: 2101-2111, 1993.
58. Strauss LG: Assessment of gastrointestinal tumors with PET. In: Clinical PET. Bares R and Lucignani G (eds). Kluwer Academic Publishers, pp45-54, 1996.
59. Bares R: Assessment of hematological malignancies with PET. In: Clinical PET. Bares R and Lucignani G (eds). Kluwer Academic Publishers, pp67-74, 1996.
60. Rege SD, Chaiken L and Hoh CK: Change induced by RT in FDG uptake in normal and malignant structures of head and neck. Radiology 189: 807-812, 1993.
61. Torizuda T, Tamaki N and Inokuma T: Value of F-18 FDG PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 35: 1965-1969, 1994.
62. Dietlein M, Sheidhauer K, Voth E, Theissen P and Schicha H: F-18 FDG PET and I-131 whole-doby scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24: 1342-1348, 1997.
63. Sonoda Y, Kumabe T, Takahashi T, Shirane R and Yoshimoto T: Clinical usefulness of C-11-MET PET and Tl-201 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir 38: 342-347, 1998.
64. Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, Zheng M, Lewellen B, Lewellen TK, Grierson JR and Krohn KA: Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 39: 1757-1762, 1998.
65. Jacobson AF and Fogelman I: Bone scanning in clinical oncology: does it have a future? Eur J Nucl Med 25: 1219-1223, 1998.
66. Goldman S, Wikler D, Damhout P, Monclus M, Levivier M, Pierotte B, De Witte O, Brotchi J and Hildebrand J: Positron emission tomography and brain tumours. Acta Neurol Belg 97: 183-186, 1997.
67. Schapira DV and Urban N: A minimalist policy for breast cancer surveillance. JAMA 265: 380-382, 1991.
68. Werthaeimer MD: Against minimalism in breast cancer follow-up. JAMA 265: 396-397, 1991.
69. Cocconi G: Follow-up of patients with breast cancer. JAMA 272: 1657-1658, 1994.
70. Becker W: A changing role for bone scintigraphy in oncology: the road from routine imaging screening to patient-based screening. Eur J Nucl Med 25: 1359-1361, 1998.
71. Bares S: Skeletal scintigraphy in breast cancer management. Q J Nucl Med 42: 43-48, 1998.
72. Bombardieri E, Maffioli L, Correale M, Abbate I and Steens J: Nuclear medicine approach in the visualization and characterization of lung cancer. In: Recent Advances in Lung Cancer. Carpagnano F and De Lena M (eds). Masson, Milano, pp47-62, 1995.
73. Valdes Olmos RA: Functional analysis of cancer therapy effects in other organs. In: Nuclear Medicine. Murray IPC and Ell PJ (eds). Churchill Livingstone, pp897-906, 1994.
74. Estorch M, Carrio I and Berna L: Indium 111 antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med 31: 1965-1969, 1990.
75. Carrio I, Estorch M and Lopez A: Assessing anthracycline toxicity in the 1990s. Eur J Nucl Med 23: 359-364, 1996.
76. Skinner R, Pearson ADJ and Coulthard MC: Assessment of chemotherapy associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol 28: 81-92, 1991.
77. Dewit L, Anninga JK, Hoefnagel CA and Nooijen WJ: Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical end points. Int J Radiat Oncol Biol Phys 19: 977-983, 1990.
78. Sonmezoglu K, Erdil TY, Demir M, Sayman HB, Kabasakal L, Yardi OF, Ozkara H, Mat MC, Solanki K and Britton KE: Evaluation of renal function in low-dose cyclosporine-treated patients using technetium-99m diaminocyclohexane: a cationic tubular excretion agent. Eur J Nucl Med 25: 1630-1636, 1998.
79. Kataoka M, Kawamura M, Itoh H and Hamamoto K: Ga-67 citrate scintigraphy for the early detection of radiation pneumonitis. Clin Nucl Med 17: 27-31, 1992.
80. Awad HK: Early reacting tissues: the digestive tract. In: Radiation Oncology. Kluwer, Dordrecht, pp512-540, 1991.
81. 131I therapy in thyroid cancer on the function of salivary glands. Acta Endocrinol 252: 73-74, 1983.
82. Reske SN: Recent advances in bone marrow scanning. Eur J Nucl Med 18: 203-221, 1991.
83. Stokkel MP, Valdes Olmos RA, Hoefnagel CA and Richel DJ: Tumor and therapy associated abnormal changes in bone scintigraphy: old and new phenomena. Clin Nucl Med 18: 821-828, 1993.
84. Mankin HJ: Non traumatic necrosis of bone. N Engl J Med 326: 1473-1478, 1992.
85. 99mTc HMPAO SPECT imaging of treated childood brain tumors. Pediatr Neurol 7: 249-257, 1991.
86. Coleman RE, Hoffman JM, Manson MW, Sostman HD and Schold SC: Clinical application of PET for the evaluation of brain tumors. J Nucl Med 32: 616-622, 1991.
87. Bishof Delaloye A: Highlight of the Annual Meeting of the EANM, Copenhagen 1996. Nuclear medicine 100 years after the discovery of radioactivity. Eur J Nucl Med 24: 219-232, 1997.
88. Spencer RP: Tumor seeking radiopharmaceuticals: nature and mechanisms. In: Nuclear Medicine. Murray IPC and Ell PJ (eds). Chirchill Livingstone, pp711-725, 1994.
89. 99mTc SestaMIBI scintimammography for the evaluation of breast lesions. In: Radionuclide Imaging of the Breast. Taillefer R, Khalkhali I, Waxman AD and Biersack HJ (eds). Marcel Dekker Inc., New York, pp371-396, 1998.
90. Guleg SA, Moffat FL, Carroll RG, Serafini A, Sfakianakis GN, Allen L, Boggs J, Escobedo D, Pruett CS, Gupta A, Livingstone AS and Krag DN: Sentinel lymph node localization in early breast cancer. J Nucl Med 39: 1388-1393, 1998.
91. Adams S, Baum RP, Hertel A, Wenisch HJC, Staib-Sebler E, Herrmann G, Encke A and Hor G: Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med 39: 1155-1160, 1998.
92. Van der Veen H, Hoekstra OS, Paul MA, Cuesta MA and Meijer S: Gamma-probe-guided sentinel biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 81: 1769-1770, 1994.
93. Feine U, Leitzenmayer R and Muller-Schauenburg W: Whole body PET in oncology. In: Clinical PET. Bares R and Lucignani G (eds). Kluwer Academic Publishers, pp75-83, 1996.
94. Hoh CK, Hawkins RA and Glaspy JA: Cancer detection with whole body PET using 18F-FDG. J Comput Assist Tomocr 17: 582-589, 1993.
95. Meikle SR and Dahlbom M: Positron emission tomography. In: Nuclear Medicine. Murray IPC and Ell PJ (eds). Churchill Livingstone, pp 1327-1337, 1994.
96. Bombardieri E, Crippa F, Rossetti C and Fazio F: The need of cost-effectiveness evaluation when using high-cost equipment in national health services. Tumori 83: 544-546, 1997.
97. Valk PF, Pounds TR, Tesar RD, Hopkins DM and Haserman MK: Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 25: 737-743, 1996.
98. Gambhir SS, Hoh CK, Phelps ME, Madar I and Maddahi J: Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma. J Nucl Med 37: 1428-1436, 1996.
99. Links JM: Advances in nuclear medicine instrumentation: consideration in the design and selection of an imaging system. Eur J Nucl Med 25: 1453-1466, 1998.